samedan logo
 
 
spacer
home > pmps > winter 2017 > vanishing act
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Vanishing Act

For drugs which are administered orally – like capsules and tablets – the bioavailability of the drug and its effectiveness are dependent on its solubility in gastrointestinal fluids. Approximately 80% of new small molecule drugs emerging from discovery pipelines can be regarded as poorly soluble. It is not only the growing number of new compounds that have this problem, it is also the extent of insolubility.

Different Approaches
There are several approaches that are commonly used to improve the drug solubility in aqueous media:

Chemical Modification
If the drug substance is a weak acid or base, it may then be possible to form a salt with a suitable counter ion. Salts are often more water-soluble than the free acid or base form of the compound. However, this approach is not appropriate for neutral molecules. Also, there is no guarantee that the water solubility of the salt will be markedly greater than the free form of the drug.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Robert Harris is Chief Technical Officer at Juniper Pharma Services and has over 30 years’ experience in the pharma industry. His early career involved technical roles with Warner Lambert and Glaxo Wellcome before spending time in academia as a Research Fellow at the University of Manchester, UK, where he helped develop novel drug delivery systems.
spacer
Robert Harris
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

DFE Pharma opens its new Center of Excellence in India to provide fast-track formulation services

The new ‘Closer to the Formulator’ (C2F) center offers DFE Pharma’s excipient expertise to help pharmaceutical companies achieve ‘first-time right’ formulations.
More info >>

White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement